Physical Activity, Sleep, and Quality of Life in Pulmonary Arterial Hypertension: Novel Insights From Wearable Devices, Pulmonary Circulation, April 16, 2025

A study published in Pulmonary Circulation on April 16, 2025 investigated whether Fitbit wearable devices can provide meaningful clinical information about activity and sleep patterns in pulmonary arterial hypertension (PAH) patients. A total of 110 participants completed the 12-week baseline monitoring period. The cohort was median age 52.7 years (IQR: 40.9–60.5), female predominant (84% female), […]

Physical Activity, Sleep, and Quality of Life in Pulmonary Arterial Hypertension: Novel Insights From Wearable Devices, Pulmonary Circulation, April 16, 2025 Read Post »

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach in pulmonary hypertension, International Journal of Cardiology, May 2025 edition

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach targeting the sympathetic nervous system’s role in pulmonary hypertension, reveal the findings of a metanalysis reviewing 14 studies, involving 372 patients. Pulmonary Artery Denervation improved several key hemodynamic parameters and clinical outcomes. The meta-analysis was published in the May 2025 edition of the International Journal

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach in pulmonary hypertension, International Journal of Cardiology, May 2025 edition Read Post »

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death, New England Journal of Medicine, March 31, 2025

An article published in the New England Journal of Medicine on March 31 titled “Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death” reports on the findings of ZENITH, a phase 3 trial which evaluated sotatercept as an add-on therapy for high-risk pulmonary arterial hypertension patients (functional class II-IV) already on maximum

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death, New England Journal of Medicine, March 31, 2025 Read Post »

Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose Finding Phase 2 Study, American Journal for Respiratory Critical Care Medicine, March 2025

Imatinib for pulmonary arterial hypertension was the first antiproliferative approach in this condition’s treatment and may still be relevant today despite its complicated history. Originally developed as a cancer therapy (tyrosine kinase inhibitor), it showed very good results in pulmonary arterial hypertension, creating a lot of expectation when the IMPRES study was presented at the

Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose Finding Phase 2 Study, American Journal for Respiratory Critical Care Medicine, March 2025 Read Post »

Hoarseness as a rare symptom of idiopathic pulmonary arterial hypertension due to Ortner Syndrome, American Journal of Case Reports, March 28, 2025

The case study reported in a recent article for the American Journal of Case Reports, describes a 32-year-old male patient with idiopathic pulmonary arterial hypertension (IPAH) who presented with hoarseness. The hoarseness was attributed to Ortner syndrome, where an enlarged pulmonary artery compressed the left recurrent laryngeal nerve, causing left vocal fold paralysis. Diagnostic workup

Hoarseness as a rare symptom of idiopathic pulmonary arterial hypertension due to Ortner Syndrome, American Journal of Case Reports, March 28, 2025 Read Post »

The first edition of the year of the UK’s Pulmonary Hypertension’s EMPHASIS magazine is now out

EMPHASIS is the quarterly magazine of the UK Pulmonary Hypertension Association, PHA UK. You can read it at this link on the PHA UK website. This edition contains news of patient meetings, an update on sotatercept and an analysis of the future of research, a number of patient stories, an article on self identity and

The first edition of the year of the UK’s Pulmonary Hypertension’s EMPHASIS magazine is now out Read Post »

March is Nutrition Month in the US, here are some tips from the US Pulmonary Hypertension Association, PHA

March is National Nutrition Month in the US, and the Pulmonary Hypertension Association has shared a LinkedIn post highlighting nutrition awareness for pulmonary hypertension patients. The organization encourages patients to be especially mindful of their dietary choices, as certain foods and vitamins can adversely interact with pulmonary hypertension medications, worsen edema (fluid retention), or exacerbate

March is Nutrition Month in the US, here are some tips from the US Pulmonary Hypertension Association, PHA Read Post »

Pregnancy and pulmonary arterial hypertension: Management challenges, International Journal of Cardiology Congenital Heart Disease, March 2025

This article, published in the International Journal of Cardiology Congenital Heart Disease in March 2025, discusses pulmonary hypertension in pregnancy, historically associated with poor outcomes, and provides recent evidence suggesting that the prognosis varies based on underlying cause and severity. The authors emphasize the need for individualized care through a multidisciplinary team approach at tertiary

Pregnancy and pulmonary arterial hypertension: Management challenges, International Journal of Cardiology Congenital Heart Disease, March 2025 Read Post »

Latest edition of “Pathlight”, the US Pulmonary Hypertension Association’s quarterly magazine, now out!

The latest issue of the quarterly Pathlight magazine of the US Pulmonary Hypertension Association, the PHA, celebrates pulmonary hypertension heroes. As National Volunteer Month approaches, the association acknowledges the people who make this organization a success. This issue also includes articles about imaging innovations, managing medication side effects and swimming with subcutaneous therapy.  To receive

Latest edition of “Pathlight”, the US Pulmonary Hypertension Association’s quarterly magazine, now out! Read Post »

Should sex differences be taken into account when conducting a risk assessment for pulmonary arterial hypertension patients? International Journal of Cardiology, March 20, 2025

In a multicenter study from the FOCUS-PAH registry (2001-2022), researchers examined sex differences among 410 pulmonary arterial hypertension patients, and found that women represented 2 out of 3 patients (66.6 %) vs 33.4%). The findings, published in the International Journal of Cardiology on March 20, 2025 in an article titled “Sex differences in pulmonary arterial

Should sex differences be taken into account when conducting a risk assessment for pulmonary arterial hypertension patients? International Journal of Cardiology, March 20, 2025 Read Post »

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis, ESC Heart Failure, March 4, 2025

A recent study published in ESC Heart Failure (March 4, 2025) compared initial monotherapy versus combination therapy in pulmonary arterial hypertension (PAH) patients with cardiovascular comorbidities. Results showed that the combination therapy group experienced greater improvements in functional class, BNP/NT-proBNP levels, and overall risk status compared to monotherapy patients. However, no significant differences were observed

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis, ESC Heart Failure, March 4, 2025 Read Post »

“Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox”, International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025)

A recent analysis published in the International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025) examines the evolving landscape of pulmonary arterial hypertension (PAH). While traditionally viewed as primarily affecting young adult women without other health conditions, newer registry data from developed countries reveals a shift toward older patients with multiple co-morbidities like

“Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox”, International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025) Read Post »

Revisiting treatment of pulmonary arterial hypertension in the current era: A Greek scientific document, Hellenic Journal of Cardiology, February 19, 2025

The authors of the study “Revisiting treatment of pulmonary arterial hypertension in the current era: A Greek scientific document” published in the Hellenic Journal of Cardiology on February 19, 2025, presents a country-specific approach to care developed by a multidisciplinary team of cardiologists, pulmonologists, and intensivists. The authors discuss the advances in the field of

Revisiting treatment of pulmonary arterial hypertension in the current era: A Greek scientific document, Hellenic Journal of Cardiology, February 19, 2025 Read Post »

Miniature three dimensional arterial structures may allow proxy evaluation of human pulmonary artery contractility, British Journal of Pharmacology, February 20, 2025

The authors of a study titled “Engineered pulmonary artery tissues for measuring contractility, drug testing and disease modelling”, published in the British Journal of Pharmacology on Ferbruary 20, 2025, present an innovative technique to allow proxy evaluation of human pulmonary artery contractility. Vasoreactivity of the pulmonary arteries regulates blood flow through the lungs,they say, and

Miniature three dimensional arterial structures may allow proxy evaluation of human pulmonary artery contractility, British Journal of Pharmacology, February 20, 2025 Read Post »

The latest National Audit of Pulmonary Hypertension in the United Kingdom shows high levels of care despite increasing number of patients

Every year, the National Audit of Pulmonary Hypertension (NAPH) measures the quality of care provided to pulmonary hypertension patients in the United Kingdom by asking specialist centres to provide data that is then compared against a set of 15 agreed standards. The latest audit, covering 2023-24, shows that high levels of care continue – despite centres seeing

The latest National Audit of Pulmonary Hypertension in the United Kingdom shows high levels of care despite increasing number of patients Read Post »

Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients, The Lancet, February 20, 2025

An article titled “Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients”, was published in The Lancet on February 20, 2025. It reports on discussions held between a group of international experts at the 20th Global CardioVascular Clinical Trialists Forum, CVCT (Washington DC, USA), patients’ representatives, and members

Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients, The Lancet, February 20, 2025 Read Post »

A proposal to involve people living with rare and complex conditions in the development of clinical practice guidelines, Patient Education and Counseling, February 19, 2025

The objective of the study published on February 19, 2025 as a Journal pre proof on Patient Edcuation and Counseling (§), is to develop a proposal to involve people living with rare and complex conditions in the development of clinical practice guidelines, based on a systematic review of qualitative literature (64 publications). The authors offer

A proposal to involve people living with rare and complex conditions in the development of clinical practice guidelines, Patient Education and Counseling, February 19, 2025 Read Post »

Medication Non-Adherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association (PHA) Registry (PHAR), Annals of the American Thoracic Society, February 18, 2025

Medication non-adherence in pulmonary arterial hypertension (PAH) can significantly impact patient outcomes, yet its prevalence and consequences remain understudied. This multi-center registry analysis examined self-reported non-adherence rates among pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (CTEPH) patients, identifying key socioeconomic predictors and associated healthcare outcomes. Using data from the Pulmonary Hypertension Association Registry (PHAR),

Medication Non-Adherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association (PHA) Registry (PHAR), Annals of the American Thoracic Society, February 18, 2025 Read Post »

Polish version of the Health Policy Partnership’s pulmonary arterial hypertension policy toolkit presented in Warsaw at the Healthcare Priorities Conference, January 29, 2025

Following the official launch of its pulmonary arterial hypertension policy toolkit in Barcelona last November at PHAEUROPE‘s Annual Conference, The Health Policy Partnership has been working on dissemination opportunities of this important work, which was endorsed by the Alliance for Pulmonary Hypertension along with several of the major patient associations active in the field. On

Polish version of the Health Policy Partnership’s pulmonary arterial hypertension policy toolkit presented in Warsaw at the Healthcare Priorities Conference, January 29, 2025 Read Post »

How to deal with setbacks when managing pulmonary arterial hypertension, Pulmonary Hypertension News, January 29, 2025

This article by Jen Cueva, a pulmonary hypertension patient, reflects on the challenges of managing setbacks, particularly for those with pulmonary arterial hypertension and other chronic conditions, emphasizing that setbacks are not failures but may represent opportunities to adjust and persevere. It highlights the importance of self-compassion, rest, and leaning on support systems to navigate

How to deal with setbacks when managing pulmonary arterial hypertension, Pulmonary Hypertension News, January 29, 2025 Read Post »

TRANSLATE »
Scroll to Top